Data Published in Nature Communications Highlights Unique Mechanism of Action of Alpibectir in Combination with Ethionamide (AlpE) Apr 13, 2026 01:00AM
BioVersys doses first patient in phase 2b tuberculosis trial Mar 12, 2026 02:00AM
BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis Mar 12, 2026 02:00AM
BioVersys tuberculosis drug study results published in medical journal Feb 19, 2026 01:00AM
BioVersys and Partners’ Phase 2a Tuberculosis Trial Results Published in New England Journal of Medicine Feb 19, 2026 01:00AM


Dec 11, 2025 01:00AM BioVersys initiates Phase 3 trial for antibiotic candidate BV100
Dec 11, 2025 01:00AM BioVersys Announces BV100 Phase 3 Initiation and Provides a Business Update
Jan 15, 2025 07:00AM Presenting on the Emerging Growth Conference 78 Day 2 on January 16 Register Now
Dec 4, 2024 07:00AM Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now
Oct 29, 2024 07:00AM Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now